Amgen | AMGN


EPS Reference Time Actual Consensus Previous
2026-07-30 FY2026Q2 PM 5.59 6.02
2026-04-30 FY2026Q1 PM 5.15 4.79 4.90
2026-02-03 FY2025Q4 PM 5.29 4.72 5.31
2025-11-04 FY2025Q3 PM 5.64 5.07 5.58
2025-08-05 FY2025Q2 PM 6.02 5.23 4.97



Peers Price Chg Day Year Date
Takeda 5,332.00 -66.00 -1.22% 21.79% Jul/10
AbbVie 249.91 -2.83 -1.12% 28.16% Jul/09
Agios Pharmaceuticals 42.80 0.04 0.09% 8.27% Jul/09
ALKERMES 53.80 -0.49 -0.90% 76.63% Jul/09
Amgen 363.61 -4.38 -1.19% 21.05% Jul/09
Biogen 198.91 -1.45 -0.72% 46.98% Jul/09
BioMarin Pharmaceutical 60.01 0.26 0.44% 2.02% Jul/09
Bristol-Myers Squibb 57.94 0.40 0.70% 19.41% Jul/09
Coherus Biosciences 1.63 -0.02 -1.21% 87.96% Jul/09
Exelixis 57.10 0.99 1.76% 26.41% Jul/09

Indexes Price Day Year Date
US500 7528 60.93 0.81% 20.26% Jul/10
USND 26207 336.24 1.30% 27.03% Jul/09
US30 52423 139.02 0.27% 18.15% Jul/10
US100 29523 474.54 1.62% 29.60% Jul/10

Amgen traded at $363.61 this Thursday July 9th, decreasing $4.38 or 1.19 percent since the previous trading session. Looking back, over the last four weeks, Amgen lost 7.66 percent. Over the last 12 months, its price rose by 21.05 percent. Looking ahead, we forecast Amgen to be priced at 366.33 by the end of this quarter and at 343.84 in one year, according to Trading Economics global macro models projections and analysts expectations.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.



News Stream
Amgen Stock Price Hits 11-week High
Amgen shares increased to 358.73 USD, the highest since April 2026. Over the past 4 weeks, Amgen gained 6.78%, and in the last 12 months, it increased 28.52%.
2026-06-25
Amgen Stock Price Hits 5-week High
Amgen shares increased to 345.87 USD, the highest since April 2026. Over the past 4 weeks, Amgen gained 6.8%, and in the last 12 months, it increased 20.51%.
2026-06-04
Amgen Stock Price Hits 14-week Low
Amgen shares decreased to 334.00 USD, the lowest since January 2026. Over the past 4 weeks, Amgen lost 3.77%, and in the last 12 months, it increased 16.38%.
2026-04-29